… over erlotinib alone for EGFR-mutant advanced NSCLC patients. This meta-analysis … a
first-line treatment for EGFR-mutant NSCLC patients. Among the five trials included in our …

… Nine studies comprising 1698 patients with NSCLC were included in this meta-analysis, of
whom 850 were treated with erlotinib plus bevacizumab, and 848 with erlotinib. The erlotinib …

… We performed a standard pairwise IVhet meta-analysis of direct comparisons for each
outcome. Since only 11 studies directly compared afatinib and erlotinib, they had pooled effect …

… plus bevacizumab in the treatment of patients with advanced EGFRm + NSCLC. Thus, the …
meta-analysis was to evaluate the effects and safety of erlotinib plus bevacizumab in patients …

… non-small cell lung cancer (NSCLC) is increasing. Materials and Methods: We performed a
meta-analysis … ) in older adult patients with advanced EGFR-mutated NSCLC. A total of 1327 …

Background Despite the well‐established efficacies of tyrosine kinase inhibitors (TKIs) in
epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC), there …

Aim: The objective of this network meta-analysis was to determine the most useful first-line
therapeutic strategy for patients with advanced (IIIB/IV or relapsed) non–small cell lung …

… erlotinib and bevacizumab. To resolve these issues, we conducted a meta-analysis and …
We compared the effects of erlotinib+bevacizumab combination therapy with the respective …

… Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are the current
standard of care for advanced or metastatic non-small cell lung cancer (NSCLC) patients …

… Subgroup analysis of PFS: the purpose of this meta-analysis was to explore the efficacy and
safety of combined medications, and simultaneously to conduct a subgroup analysis of PFS …